Guselkumab/Golimumab

古塞奇尤单抗/戈利木单抗

Report date: 2026/05/12 20:00:17

Base Information

Drug NameGuselkumab/Golimumab
Drug Alias NameGuselkumab/Golimumab古塞奇尤单抗/戈利木单抗JNJ-78934804
ClassificationBiologics
Mechanisms of ActionInterleukin-23 subunit p19 inhibitorsTumor necrosis factor α inhibitors
TargetsInterleukin-23 subunit p19Tumor necrosis factor α
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsYes GuselkumabGolimumab
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdCilag AgJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A